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Viral and cellular oncogenes converge in targeting critical protein interaction networks to reprogram the
cellular DNA and protein replication machinery for pathological replication. In this issue, Thai et al. (2014)
show that adenovirus E4ORF1 activates MYC glycolytic targets to induce aWarburg-like effect that converts
glucose into nucleotides for viral replication.Adenovirus is a small (36 kb) double-
stranded DNA virus that expresses
‘‘early’’ E1 and E4 proteins that hijack
cellular growth regulatory networks to
replicate the viral genome and proteins.
Many of these early proteins are oncopro-
teins and have led to the discovery of key
cellular targets and mechanisms that
are also deregulated in cancer, including
E2F and Rb tumor suppressor proteins
(Ou et al., 2011). One of the hallmarks of
cancer is a tendency to ferment glucose
to lactose even when sufficient oxygen is
available to support mitochondrial oxida-
tive phosphorylation (Ward and Thomp-
son, 2012). This is known as the Warburg
effect, which is less efficient in terms of
ATP generation (2 versus 36 ATPs), but
enables glucose to be used as a carbon
source for the synthesis of nucleotides,
amino acids, and lipids in cell growth
and division. In this issue, Thai et al.
(2014) reveal adenovirus infection as a
novel model to identify cellular mecha-
nisms that reprogram metabolism. They
show that adenovirus infection decreases
cellular respiration and induces a rapid
Warburg-like shift to glycolysis, providing
a powerful genetic system to reveal the
dynamics and key network interactions
that reprogram metabolism in a single
cell cycle.
Countless generations of propagation
and selective pressure have driven the
evolution of both minimal adenovirus ge-
nomes and ‘‘early’’ proteins that attack
critical cellular hubs to elicit pathological
replication (Ou et al., 2011). Thai et al.
exploit both the genetic and biochemical
power of viruses to reveal new insights
into molecular mechanisms that repro-
gram cellular metabolism. In contrast to
wild-type Ad5, DE4 adenovirus mutants
are defective for inducing glycolysis and
decreased respiration. They show thatthe gene product of adenovirus E4ORF1
enhancesglycolytic fluxbut notdecreased
oxygen consumption. E4ORF1 is thought
to have evolved from dUTP pyrophospha-
tases, losing enzymatic activity along the
way and acquiring novel transforming
properties (Chung et al., 2007). This in-
cludes a PDZ binding motif that binds to
cellular PDZ-containing proteins, such as
DLG and MUPP1, and is required for the
activation of PI3 kinase (PI3K). PI3K activ-
ity is also targeted by growth factor
pathway mutations in cancer and upre-
gulates glucose transporter expression
and hexokinase activity, rendering cells
dependent on glucose flux (Ward and
Thompson, 2012). However, defying a
seemingly obvious mechanistic connec-
tion, E4ORF1 DPDZ mutants still induce
the glycolytic shift.
E4ORF1 also localizes to the nucleus,
but its functions there have been unclear.
In the search for a link to metabolism, Thai
et al. show that E4ORF1 increases MYC
levels in the nucleus and induces global
gene expression changes that are en-
riched for a MYC signature. MYC is a
multifunctional transcription factor that is
the driving oncogenic translocation in
Burkitt’s lymphoma and amplified or up-
regulated in many tumors (Dang, 2012).
MYC binds to E-box sequences and can
potentially modulate up to a third of
the human transcriptome. MYC levels
are normally tightly regulated through
rapid mRNA and protein turnover (Farrell
and Sears, 2014). E4ORF1 and E4ORF6
coimmunoprecipitate with MYC in the nu-
cleus, potentially stabilizing MYC through
direct interactions. The authors show that
E4ORF1 D68A mutants that are defective
for PI3K activation and cellular transfor-
mation (Chung et al., 2007) also exhibit
reduced binding to MYC and E4ORF6.
These data indicate that D68A mutantsCell Metabolismare hypomorphic, perhaps due to protein
aggregation. WT E4ORF1, but not D68A
mutants, induces MYC activation of a
subset of glycolytic targets, including
HK2 and PFKM (Figure 1). Although the
effects on HK2 mRNA levels are modest,
it may be rate limiting, and the overex-
pression of HK2 is sufficient to enhance
glycolysis to a similar extent as E4ORF1.
MYC shRNA inhibits the glycolytic shift
and virus replication. However, MYC
also cooperates with E2F to drive DNA
replication. Therefore, it will be important
to determine the specific contribution of
MYC metabolic targets, such as HK2, in
viral replication.
In an elegant series of experiments,
Thai et al. use positional glucose tracers
to demonstrate that glycolysis gener-
ates metabolites for increased nucleotide
biosynthesis in adenovirus-infected cells.
An E4ORF1 D68A mutant adenovirus that
fails to induce the glycolytic shift is defec-
tive for replication. However, E4ORF1
D68A mutant viruses also fail to activate
PI3K. Therefore, to determine the specific
contribution of metabolic reprogramming
in viral replication will require E4ORF1
mutations that selectively uncouple its
functions in MYC-induced glycolysis
from its other cellular activities and tar-
gets in infection.
The mechanism through which E4ORF1
enhances MYC activity at a subset of
glycolytic target genes remains unknown.
E1A, the master adenovirus oncogene,
also induces and stabilizes MYC (Chakra-
borty and Tansey, 2009; Kadeppagari
et al., 2009). However, E1A is not sufficient
to induce MYC metabolic targets in E4
mutant virus-infected cells. Thus, E1A
and E4ORF1 may directly specify MYC-
activated transcription of cell cycle
and metabolism genes, respectively, or
target its recruitment through distinct19, April 1, 2014 ª2014 Elsevier Inc. 549
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Figure 1. Adenovirus Oncoproteins Reprogram Cellular Metabolism at Multiple Signaling
and Transcriptional Nodes to Induce a Glycolytic Shift that Converts Glucose into the
Molecular Building Blocks Required for Viral Replication
Adenovirus E4ORF1 binds to MYC in the nucleus to activate the transcription of a subset of glycolytic
target genes, HK2 and PFKM, that promote a Warburg-like shift to aerobic glycolysis. The activation of
MYC, PI3K, and mTOR by E4ORF1 and additional adenovirus oncoproteins could have emergent
functions in reprogramming cellular metabolism to synthesize proteins and nucleic acids required for viral
replication.
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Previewscollaborating cofactors. Alternatively, the
temporal kinetics of E1A and E4ORF1
expression in infection could induce
different MYC levels that determine the
activation of cell cycle and metabolic
promoters. Distinguishing between these
possibilities is critical for the development
of strategies that selectively target MYC’s
oncogenic effects in tumor metabolism
and growth. As such, adenovirus infection
could prove a powerful system to recon-
cile the raging contemporary debate as
to whether MYC amplifies rather than
specifies transcriptional reprogramming
(Lin et al., 2012).
These studies reinforce the profound
overlap that exists between the cellular
targets and phenotypes of tumor and viral
replication (Ou et al., 2011). Both viral and
cellular oncogenes divert glucose into
energetically costly anabolic pathways to
generate macromolecular building blocks
for replication. Similar to other DNA550 Cell Metabolism 19, April 1, 2014 ª2014viruses, adenovirus increases glycolysis,
mirroring the Warburg effect in cancer.
E4ORF1 has evolved independent mech-
anisms to usurp two of the major meta-
bolic nodes targeted by tumor pathway
mutations, PI3K andMYC. Although these
E4ORF1 interactions may be indepen-
dent, they could have synergistic effects
in reprogramming metabolism. PI3K-
induced activation of AKT can prevent
GSK3b-induced phosphorylation of MYC
at Thr58, thereby stabilizing MYC (Farrell
and Sears, 2014). In addition, adenovirus
E4ORF4 phenocopies glucose in acti-
vating mTOR (O’Shea et al., 2005). The
activation of MYC, PI3K, andmTOR could
have emergent functions in reprogram-
ming metabolism to synthesize proteins
and nucleic acids for viral replication
(Figure 1). It will be intriguing to determine
if the functions of Ad5 E4ORF1 in acti-
vating MYC and glycolysis are conserved
across all human adenoviruses. Interest-Elsevier Inc.ingly, Ad36 infection and E4ORF1 have
been reported to improve glycemic con-
trol, which has been suggested as a
possible approach to treat hepatic steato-
sis and diabetes (Dhurandhar et al., 2012).
One thing is certain: metabolism is going
viral, revealing exciting new insights into
the dynamics of cellular network interac-
tions that are rewired to elicit pathological
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